Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

6 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(100.0%)
6Total
Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00273481Phase 4Completed

Cosopt Versus Xalacom

Role: lead

NCT00273455Phase 4Completed

Lumigan Versus Cosopt

Role: lead

NCT00273442Phase 4Completed

Assessing Cosopt Switch Patients

Role: lead

NCT00304785Phase 4Completed

Latanoprost Versus Fotil

Role: lead

NCT00273429Phase 4Completed

Cosopt Versus Xalatan

Role: lead

NCT00284999Phase 4Completed

Soothe Versus Refresh

Role: lead

All 6 trials loaded